Stocksigma LogoStocksigma Logo

Zydus Receives USFDA Approval for Estradiol and Levonorgestrel Transdermal System

Zydus Lifesciences received final USFDA approval for its generic Estradiol and Levonorgestrel Transdermal System (0.045 mg/0.015 mg/day), referenced to

Zydus Receives USFDA Approval for Estradiol and Levonorgestrel Transdermal System

Zydus Lifesciences Ltd 路 Press Release 路 21 Oct 2026, 4:42 pm

Zydus Receives USFDA Approval for Estradiol and Levonorgestrel Transdermal System Zydus Lifesciences received final USFDA approval for its generic Estradiol and Levonorgestrel Transdermal System (0.045 mg/0.015 mg/day), referenced to Climara Pro. Designated as a Competitive Generic Therapy (CGT), the product is eligible for 180 days of marketing exclusivity upon commercial launch. Indicated for menopause symptoms and osteoporosis prevention, it will be manufactured at Moraiya, Ahmedabad. The drug registered annual US sales of ~$45.7 mn (IQVIA MAT Aug'26). As of 30th Sep'26, Zydus holds 458 USFDA approvals and 516 filed ANDAs.

Original exchange filing (PDF)

More announcements from Zydus Lifesciences Ltd

All Zydus Lifesciences Ltd announcements